UHealth - University of Miami Health System

E-mail a Friend

Charles L. Vogel, M.D.

General Information

Charles L. Vogel, M.D.


  • Fax: 954-571-0118


  • Internal Medicine
  • Hematology/Oncology - Internal Medicine




  • American Board of Internal Medicine
  • American Board of Internal Med-Medical Oncology


  • Professor of Medicine Clinical Educator Track


  • Pollan M, Pajares B, Martin M, Mackey J, Lluch A, Ruiz A, Vogel C, Borrego MR, Calvo L, Pienkowski T, Lescure AR, Segui MA, Tredan O, Anton A, Ramos M, Camara MC, Roddriguez-Martin C, Carrasco E, Alba E. The effect of obesity on prognosis in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to intrinsic subtypes. Poster ASCO 2013.
  • Michiels S, Pugliano L, Grun D, Barinoff J, Cameron D, Cobleigh M, DiLeo A, Johnston S, Gasparini G, Kaufman B, Marty M, Nekjudova V, Paluch-Shimon S, Penault-Llorca F, Slamon D, Vogel C, von Minckwitz G, Buyse M, Piccart M. Progression –free survival (PFS) as surrogate endpoints for overall survival (OS) in clinical trials of Her-2-targeted agents in HER2-positive metastatic breast cancer (MBC): an individual patient data (IPD) analysis. Poster ASCO 2013
  • Love N: Moderator. Audiotape Gonzalez-Angulo AM, Gradishar WJ, Hayes DF, Krop IE, Linden HM, Mamounas EP, Miller KD, Vogel CL. Breast Cancer Update Think Tank. Issue #1 2012
  • Mayer E, Miller K, O’Shaughnessy J, Dickler M, Vogel C, Leyland-Jones, B, Steelman L, Robinson M, Kurzyama N, Agarwal S. Tivozanib in combination with paclitaxel vs placebo in patients with locally advanced or metastatic triple-negative breast cancer. Ca Res 72 (#24, suppl 3) OT-2-3-11, pg 43s, 2012
  • Ambros T, Zeichner S, Zaravinos J, Montero A, Ahn E, Mani A, Kronish L, Mahtani R, Vogel CL. The efficacy and toxicity of low-dose capecitabine in Her-2 negative breast cancer. Ca Res: 72 (#24, suppl 3) P-1-12-03, pg 192s, 2012


Best Doctors in America- Every year since inception
Invited Participant Secretary of Health
United States Public Health Service


1966-1969 Fellowship
National Institutes of Health: Bethesda, MD
1965-1966 Residency
Grady Memorial Hospital: Atlanta, GA
1964-1965 Internship
Grady Memorial Hospital: Atlanta, GA
1964 Graduate School
Yale University: New Haven, CT


Charles Vogel, MD is a board certified medical oncologist. His clinical and research interests involve all medical aspects of breast cancer treatment including anti-hormonal therapy, chemotherapy and "targeted therapy." During his 35 years of breast cancer research, he has participated in clinical trials of virtually every medical breast cancer treatment currently available. He was one of the clinical trial pioneers in Trastuzumab (Herceptin) therapy and more recently with Bevacizimab (Avastin) and Lapatanib (Tykerb). He was also one of the early pioneers in the development of clinical trials from within community practice. Currently the "Cancer Research Network" he founded has become the community clinical trials outreach program for the University of Miami. Dr. Vogel continues his interest in breast cancer clinical trials both through his involvement with the Breast Site Group of the Sylvester Comprehensive Cancer Center and through similar interactions with community oncologists within the Cancer Research Network.


E-mail a Friend